It Now Seems Possible to Vaccinate Against Cancer (Economist)

Summary

Interim phase 3 results (19 August 2026) for intismeran autogene, a personalised mRNA cancer vaccine from Moderna and Merck given alongside the checkpoint inhibitor pembrolizumab (Keytruda), slowed recurrence of melanoma in patients whose tumours had been surgically removed. The Economist reads this as the first real validation of the "neoantigen" idea after decades of failed cancer vaccines — while listing heavy caveats. The same column notes that daraxonrasib (see A New Drug Targets One of Cancers Master Switches (Economist)) received FDA approval on 26 August 2026.

Key claims

• Why vaccines failed before: single-protein targets could be dropped by the tumour; some early vaccines aimed at the wrong proteins; and tumours actively suppress immune responses. Checkpoint inhibitors remove that suppression, which revived the question of whether vaccines would work alongside them.
• What changed: mRNA lets a vaccine tailored to the neoantigens of one patient's tumour be made in weeks rather than months, making personalised vaccination practical.
• Population and result: patients with completely resected melanoma (trade coverage: stage IIB–IV cutaneous melanoma, no prior systemic therapy); vaccine + pembrolizumab delayed recurrence versus pembrolizumab alone. The interim release met the primary endpoint (recurrence-free survival) and a key secondary endpoint (distant metastasis-free survival); hazard ratios, absolute event rates and p-values were not released.
• Clinician read: Elad Sharon (Dana-Farber) calls it "promising for the field of melanoma and cancer as a whole."
• Proposed role: hunting down microscopic residual cell clusters left after surgery, potentially reducing reliance on radiation and chemotherapy.
• Pipeline: Moderna and Merck are running trials in lung, bladder and kidney cancers.

What the article flags as unproven

• Delayed recurrence may or may not translate into longer overall survival.
• Neither the size of the effect nor the cost is known — the benefit could be "marginal ... at great expense".
• Melanoma is among the most immunogenic cancers; what works here may not transfer to other tumours.
• Full melanoma results and the other-tumour trials are needed before calling it a breakthrough.

Wikilinks

Cancer Vaccines — concept page: neoantigens, checkpoint pairing, the personalised-mRNA route. KRAS Inhibitors — the other 2026 oncology milestone the column bookends with (daraxonrasib approval). Lung Cancer Screening and Prevention — lung cancer is one of the next trial targets for the vaccine. The Economist — Science & technology.

Captured-by trigger

Source file: raw/processed/Economist 2026-08-29 Science---Techn - It now seems possible to vaccinate against cancer.md.